Literature DB >> 24970104

C. difficile ribotype 027 or 176?

Marcela Krutova1, Jana Matejkova, Otakar Nyc.   

Abstract

Clostridium difficile is a major nosocomial pathogen of present times. The analysis of 624 C. difficile strains from 11 hospitals in the Czech Republic in 2013 revealed that 40% of isolates belonged to ribotype 176. These results suggest that the incidence of CDI (C. difficile infection) in the Czech Republic has increased probably in connection with C. difficile ribotype 176. The molecular systems Xpert C. difficile Epi assay (Cepheid Inc., Sunnyvale, CA) diagnoses toxigenic strains and supports C. difficile ribotype 027 determination based on three specific target places in the toxigenic C. difficile genome. Twenty-nine strains cultivated from stool specimens were evaluated by the Xpert systems as presumed C. difficile PCR ribotype 027 were confirmed as a C. difficile ribotype 176 based on ribotyping. A further 120 C. difficile strains of ribotype 176 were examined for the presence of genes tcdB, cdtB and deletion in position 117 in the tcdC gene. Our experience shows that due to the correspondence of the target places, C. difficile ribotype 176 may be interpreted as ribotype 027 by Xpert C. difficile Epi assay (Cepheid Inc., Sunnyvale, CA). Further molecular analysis as ribotyping based on capillary electrophoresis is needed to differentiate between C. difficile ribotypes 027 and 176 for appropriate epidemiological situation control on local and national levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24970104     DOI: 10.1007/s12223-014-0323-5

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  28 in total

1.  Detection of toxigenic Clostridium difficile in diarrheal stools by rapid real-time polymerase chain reaction.

Authors:  Simon D Goldenberg; Thomas Dieringer; Gary L French
Journal:  Diagn Microbiol Infect Dis       Date:  2010-07       Impact factor: 2.803

2.  Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland.

Authors:  Otakar Nyč; Hanna Pituch; Jana Matějková; Piotr Obuch-Woszczatynski; Ed J Kuijper
Journal:  Lancet       Date:  2011-04-23       Impact factor: 79.321

3.  Advancement in the routine identification of anaerobic bacteria by MALDI-TOF mass spectrometry.

Authors:  L Coltella; L Mancinelli; M Onori; B Lucignano; D Menichella; R Sorge; M Raponi; R Mancini; C Russo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-14       Impact factor: 3.267

4.  Comparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratory.

Authors:  Valerija Zidarič; Bozena Kotnik Kevorkijan; Nadja Oresic; Sandra Janezic; Maja Rupnik
Journal:  J Med Microbiol       Date:  2011-03-03       Impact factor: 2.472

5.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

6.  Evaluation of a new commercial TaqMan PCR assay for direct detection of the clostridium difficile toxin B gene in clinical stool specimens.

Authors:  Paul D Stamper; Wisal Babiker; Romina Alcabasa; Deborah Aird; Jennifer Wehrlin; Ijeoma Ikpeama; Linda Gluck; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

7.  Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces.

Authors:  Gabriella Terhes; Edit Urbán; József Sóki; Eniko Nacsa; Elisabeth Nagy
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

Review 8.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

9.  Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes.

Authors:  E de Jong; A S de Jong; C J M Bartels; C van der Rijt-van den Biggelaar; W J G Melchers; P D J Sturm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-14       Impact factor: 3.267

10.  Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection.

Authors:  Saeam Shin; Minkyung Kim; Myungsook Kim; Heejung Lim; Heejung Kim; Kyungwon Lee; Yunsop Chong
Journal:  Ann Lab Med       Date:  2012-08-13       Impact factor: 3.464

View more
  11 in total

1.  Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.

Authors:  V Beran; E J Kuijper; C Harmanus; I M Sanders; S M van Dorp; C W Knetsch; J Janeckova; A Seidelova; L Barekova; J Tvrdik; D Chmelar; I Ciznar
Journal:  Folia Microbiol (Praha)       Date:  2017-03-22       Impact factor: 2.099

2.  Comparison of Multilocus Sequence Typing and the Xpert C. difficile/Epi Assay for Identification of Clostridium difficile 027/NAP1/BI.

Authors:  Tracy McMillen; Mini Kamboj; N Esther Babady
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

3.  A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated Diarrhea.

Authors:  Özlem Yoldaş; Mustafa Altındiş; Davut Cufalı; Gülşah Aşık; Recep Keşli
Journal:  Balkan Med J       Date:  2016-01-01       Impact factor: 2.021

4.  Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015.

Authors:  M Krutova; J Matejkova; P Drevinek; E J Kuijper; O Nyc
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-05       Impact factor: 3.267

5.  Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.

Authors:  Jiri Drabek; Otakar Nyc; Marcela Krutova; Jan Stovicek; Jana Matejkova; Radan Keil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-12-23       Impact factor: 3.944

6.  DETECTION, RIBOTYPING AND ANTIMICROBIAL RESISTANCE PROPERTIES OF CLOSTRIDIUM DIFFICILE STRAINS ISOLATED FROM THE CASES OF DIARRHEA.

Authors:  Samaneh Kouzegaran; Mahmood Ganjifard; Amir Saber Tanha
Journal:  Mater Sociomed       Date:  2016-10-17

7.  Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections.

Authors:  Jacqueline Färber; Sebastian Illiger; Fabian Berger; Barbara Gärtner; Lutz von Müller; Christoph H Lohmann; Katja Bauer; Christina Grabau; Stefanie Zibolka; Dirk Schlüter; Gernot Geginat
Journal:  Antimicrob Resist Infect Control       Date:  2017-02-15       Impact factor: 4.887

8.  The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients.

Authors:  Marcela Krutova; Vaclav Capek; Elka Nycova; Sabina Vojackova; Magda Balejova; Lenka Geigerova; Renata Tejkalova; Lenka Havlinova; Iva Vagnerova; Pavel Cermak; Lenka Ryskova; Petr Jezek; Dana Zamazalova; Denisa Vesela; Alice Kucharova; Dana Nemcova; Martina Curdova; Otakar Nyc; Pavel Drevinek
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-30       Impact factor: 4.887

9.  A global to local genomics analysis of Clostridioides difficile ST1/RT027 identifies cryptic transmission events in a northern Arizona healthcare network.

Authors:  Charles H D Williamson; Nathan E Stone; Amalee E Nunnally; Heidie M Hornstra; David M Wagner; Chandler C Roe; Adam J Vazquez; Nivedita Nandurkar; Jacob Vinocur; Joel Terriquez; John Gillece; Jason Travis; Darrin Lemmer; Paul Keim; Jason W Sahl
Journal:  Microb Genom       Date:  2019-05-20

10.  Molecular characterization of nosocomial Clostridium difficile infection in pediatric ward in Iran.

Authors:  Abolfazl Khoshdel; Roya Habibian; Neda Parvin; Abbas Doosti; Fatemeh Famouri; Ali Eshraghi; Massoud Hafizi
Journal:  Springerplus       Date:  2015-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.